The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo

被引：0
|
作者：
Niessner, H. [1 ]
Forschner, A. [1 ]
Schmitz, J. [2 ]
Schmid, A. [2 ]
Calaminus, C. [2 ]
Sinnberg, T. [1 ]
Tabatabai, G. [3 ]
Quintanilla-Fend, L. [4 ]
Pichler, B. J. [2 ]
Garbe, C. [1 ]
Meier, F. [1 ]
机构：
[1] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Preclin Imaging & Radiopharm, D-72076 Tubingen, Germany
[3] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland
[4] Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2014年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E43 / E43
页数：1
相关论文
共 50 条
  • [41] ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.
    Miller, T. W.
    Fox, E. M.
    Balko, J. M.
    Meszoely, I. M.
    Sanders, M. E.
    Kuba, M. G.
    Wagle, N.
    Garraway, L. A.
    Maira, S-M
    Arteaga, C. L.
    CANCER RESEARCH, 2011, 71
  • [42] Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor
    Hamajima, Toshihiro
    Takahashi, Fumie
    Kato, Koji
    Sugano, Yukihito
    Yamaki, Susumu
    Moritomo, Ayako
    Kubo, Satoshi
    Nakamura, Koji
    Yamagami, Kaoru
    Hamakawa, Nozomu
    Yokoo, Koji
    Fukahori, Hidehiko
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 3917 - 3924
  • [43] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [44] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    Bendell, Johanna C.
    Rodon, Jordi
    Burris, Howard A.
    de Jonge, Maja
    Verweij, Jaap
    Birle, Diana
    Demanse, David
    De Buck, Stefan S.
    Ru, Qinhua C.
    Peters, Malte
    Goldbrunner, Michael
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
  • [45] PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
    Yuan, Jing
    Mehta, Pramod P.
    Yin, Min-Jean
    Sun, Shaoxian
    Zou, Aihua
    Chen, Jeffrey
    Rafidi, Kristina
    Feng, Zheng
    Nickel, Jeffrey
    Engebretsen, Jon
    Hallin, Jill
    Blasina, Alessandra
    Zhang, Eric
    Nguyen, Leslie
    Sun, Minghao
    Vogt, Peter K.
    McHarg, Aileen
    Cheng, Hengmiao
    Christensen, James G.
    Kan, Julie L. C.
    Bagrodia, Shubha
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2189 - 2199
  • [46] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [47] Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
    Anjam-Najmedini, Ali
    Vahabpour, Rohollah
    Safaroghli-Azar, Ava
    Kazemi, Alireza
    Movahhed, Parvaneh
    Momeny, Majid
    Bashash, Davood
    ADVANCED PHARMACEUTICAL BULLETIN, 2022, 12 (03) : 613 - 622
  • [48] PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
    Chuang, Fu-Cheng
    Wang, Chih-Chun
    Chen, Jian-Han
    Hwang, Tzer-Zen
    Yeh, Shyh-An
    Su, Yu-Chieh
    PLOS ONE, 2021, 16 (01):
  • [49] In vitro and in vivo pharmacological properties of the potent phosphatidylinositol 3-kinase (PI3K) family inhibitor PI103
    Raynaud, F.
    Eccles, S.
    Clarke, P.
    Hayes, A.
    Di Stefano, F.
    Ahmad, Z.
    Guillard, S.
    Patel, S.
    Workman, P.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [50] Comparison of anti-proliferation activity of BEZ 235, a multi-step inhibitor of mTOR pathway, vs. BKM120, a pan PI3K inhibitor, in lung cancer cell lines (LCCL)
    Huang, Chao H.
    Beaudoin, Christopher
    Van Veldhuizen, Peter
    Farassati, Faris
    CANCER RESEARCH, 2014, 74 (19)
12345